Manipulating microbial metabolites for drug discovery and production

Natural Products: Drug Discovery and Therapeutic Medicine

Volumn , Issue , 2005, Pages 77-93

  Hutchinson, C Richard ^a  

^a KOSAN BIOSCIENCES INC   (United States)

Author keywords

Antibiotics; anticancer drugs; biosynthesis genes; drugs; epothilone; erythromycin; FK520; geldanamycin; polyketide; polyketide synthase; rapamycin; secondary natural products

Indexed keywords

EID: 33751241216     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59259-976-9_4     Document Type: Chapter

References (68)

1. Cragg GM, Newman DJ, Snader KM. Natural products in drug discovery and development. J Nat Prod 1997;60:52-60.
2. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 2003;66:1022-1037.
3. Hopwood DA. Forty years of genetics with Streptomyces: from in vivo through in vitro to in silico. Microbiology 1999;145:2183-2202.
4. Baltz RH. Genetic manipulation of antibiotic-producing Streptomyces. Trends Microbiol 1998;6:76-83.
5. Hutchinson CR, McDaniel R. Combinatorial biosynthesis in microorganisms as a route to new antimicrobial, antitumor and neuroregenerative drugs. Curr Opin Investig Drugs 2001;2:1681-1690.
6. Reeves CD. The enzymology of combinatorial biosynthesis. Crit Rev Biotechnol 2003;23:95-147.
7. Staunton J, Weissman KJ. Polyketide biosynthesis: a millennium review. Nat Prod Rep 2001;18:380-416.
8. Donadio S, Staver MJ, McAlpine JB, Swanson SJ, Katz L. Modular organization of genes required for complex polyketide biosynthesis. Science 1991;252:675-679.
9. Rawlings BJ. Type I polyketide biosynthesis in bacteria (Part B) (1995 to mid-2000). Nat Prod Rep 2001;18:231-281.
10. Rawlings BJ. Type I polyketide biosynthesis in bacteria (Part A-erythromycin biosynthesis) (1994 to 2000). Nat Prod Rep 2001;18:190-227.
11. Khosla C, Gokhale RS, Jacobsen JR, Cane DE. Tolerance and specificity of polyketide synthases. Annu Rev Biochem 1999;68:219-253.
12. Liou GF, Khosla C. Building-block selectivity of polyketide synthases. Curr Opin Chem Biol 2003;7:279-284.
13. Austin MB, Noel JP. The chalcone synthase superfamily of type III polyketide synthases. Nat Prod Rep 2003;20:79-110.
14. Cortes J, Haydock SF, Roberts GA, Bevitt DJ, Leadlay PF. An unusually large multifunctional polypeptide in the erythromycin-producing polyketide synthase of Saccharopolyspora erythraea. Nature 1990;348:176-178.
15. Del Vecchio F, Petkovic H, Kendrew SG, et al. Active-site residue, domain and module swaps in modular polyketide synthases. J Ind Microbiol Biotechnol 2003;30:489-494.
16. Carreras C, Frykman S, Ou S, et al. Saccharopolyspora erythraea-catalyzed bioconversion of 6-deoxyerythronolide B analogs for production of novel erythromycins. J Biotechnol 2002;92:217-228.
17. Jacobsen JR, Hutchinson CR, Cane DE, Khosla C. Precursor-directed biosynthesis of erythromycin analogs by an engineered polyketide synthase. Science 1997;277:367-369.
18. Pacey MS, Dirlam JP, Geldart RW, et al. Novel erythromycins from a recombinant Saccharopolyspora erythraea strain NRRL 2338 pIG1. I. Fermentation, isolation and biological activity. J Antibiot 1998;51:1029-1034.
19. Ruan X, Pereda A, Stassi DL, et al. Acyltransferase domain substitutions in erythromycin polyketide synthase yield novel erythromycin derivatives. J Bacteriol 1997;179:6416-6425.
20. Starks CM, Rodriguez E, Carney JR, et al. Isolation and characterization of 7-hydroxy-6-demethyl-6-deoxyerythromycin D, a new erythromycin analogue, from engineered Saccharopolyspora erythraea. J Antibiot 2004;57:64-67.
21. Petkovic H, Lill RE, Sheridan RM, et al. A novel erythromycin, 6-desmethyl erythromycin D, made by substituting an acyltransferase domain of the erythromycin polyketide synthase. J Antibiot 2003;56:543-551.
22. Stassi DL, Kakavas SJ, Reynolds KA, et al. Ethyl-substituted erythromycin derivatives produced by directed metabolic engineering. Proc Natl Acad Sci USA 1998;95:7305-7309.
23. Reid R, Piagentini M, Rodriguez E, et al. A model of structure and catalysis for ketoreductase domains in modular polyketide synthases. Biochemistry 2003;42:72-79.
24. Rodriguez E, Hu Z, Ou S, Volchegursky Y, Hutchinson CR, McDaniel R. Rapid engineering of polyketide overproduction by gene transfer to industrially optimized strains. J Ind Microbiol Biotechnol 2003;30:480-488.
25. Donadio S, McAlpine JB, Sheldon PJ, Jackson M, Katz L. An erythromycin analog produced by reprogramming of polyketide synthesis. Proc Natl Acad Sci USA 1993;90:7119-7123.
26. McDaniel R, Thamchaipenet A, Gustafsson C, Fu H, Betlach M, Ashley G. Multiple genetic modifications of the erythromycin polyketide synthase to produce a library of novel "unnatural" natural products. Proc Natl Acad Sci USA 1999;96:1846-1851.
27. Tang L, McDaniel R. Construction of desosamine containing polyketide libraries using a glycosyltransferase with broad substrate specificity. Chem Biol 2001;8:547-555.
28. Rowe CJ, Bohm IU, Thomas IP, et al. Engineering a polyketide with a longer chain by insertion of an extra module into the erythromycin-producing polyketide synthase. Chem Biol 2001;8:475-485.
29. Gaisser S, Reather J, Wirtz G, Kellenberger L, Staunton J, Leadlay PF. A defined system for hybrid macrolide biosynthesis in Saccharopolyspora erythraea. Mol Microbiol 2000;36:391-401.
30. Rix U, Fischer C, Remsing LL, Rohr J. Modification of post-PKS tailoring steps through combinatorial biosynthesis. Nat Prod Rep 2002;19:542-580.
31. Watanabe K, Wang CC, Boddy CN, Cane DE, Khosla C. Understanding substrate specificity of polyketide synthase modules by generating hybrid multimodular synthases. J Biol Chem 2003;278:42, 020-42, 026.
32. Revill PW, Voda J, Reeves CR, et al. Genetically engineered analogs of ascomycin for nerve regeneration. J Pharm Exper Ther 2002;302:1278-1285.
33. Gerth K, Bedorf N, Hoefle G, Irschik H, Reichenbach H. Antibiotics from gliding bacteria. 74. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria): production, physico-chemical and biological properties. J Antibiot 1996;49:560-563.
34. Altmann KH. Epothilone B and its analogs-a new family of anticancer agents. Mini Rev Med Chem 2003;3:149-158.
35. Myles DC. Emerging microtubule stabilizing agents for cancer chemotherapy. Annu Rep Med Chem 2002;37:125-132.
36. Chou T-C, O'Connor OA, Tong WP, et al. The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. Proc Natl Acad Sci USA 2001;98:8113-8118.
37. Tang L, Shah S, Chung L, et al. Cloning and heterologous expression of the epothilone gene cluster. Science 2000;287:640-642.
38. Molnar I, Schupp T, Ono M, et al. The biosynthetic gene cluster for the microtubule-stabilizing agents epothilones A and B from Sorangium cellulosum So ce90. Chem Biol 2000;7:97-109.
39. Lau J, Frykman S, Regentin R, Ou S, Tsuruta H, Licari P. Optimizing the heterologous production of epothilone D in Myxococcus xanthus. Biotechnol Bioeng 2002;78:280-288.
40. Tang L, Ward S, Chung L, et al. Elucidating the mechanism of cis double bond formation in epothilone biosynthesis. J Amer Chem Soc 2004;126:46-47.
41. Arslanian RL, Tang L, Blough S, et al. A new cytotoxic epothilone from modified polyketide synthases heterologously expressed in Myxococcus xanthus. J Nat Prod 2002;65:1061-1064.
42. De Boer C, Meulman PA, Wnuk RJ, Peterson DH. Geldanamycin, a new antibiotic. J Antibiot 1970;23:442-447.
43. Omura S, Iwai Y, Takahashi Y, et al. Herbimycin, a new antibiotic produced by a strain of Streptomyces. J Antibiot 1979;32:255-261.
44. Sasaki K, Yasuda H, Onodera K. Growth inhibition of virus transformed cells in vitro and antitumor activity in vivo of geldanamycin and its derivatives. J Antibiot 1979;32:849-851.
45. Uehara Y, Murakami Y, Suzukake-Tsuchiya K, et al. Effects of herbimycin derivatives on src oncogene function in relation to antitumor activity. J Antibiot 1988;41:831-834.
46. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 1994;91:8324-8328.
47. Richter K, Buchner J. Hsp90: chaperoning signal transduction. J Cell Physiol 2001;188:281-290.
48. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002;8:S55-S61.
49. Goetz MP, Toft DO, Ames MM, Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 2003;14:1169-1176.
50. Schnur RC, Corman ML, Gallaschun RJ, et al. Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J Med Chem 1995;38:3806-3812.
51. Egorin MJ, Zuhowski EG, Rosen DM, Sentz DL, Covey JM, Eiseman JL. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17- demethoxygeldanamycin (NSC 330507) in CD2F1 mice. Cancer Chemother Pharmacol 2001;47:291-302.
52. Egorin MJ, Lagattuta TF, Hamburger DR, et al. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17- demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol 2002;49:7-19.
53. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17- demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999;91:1940-1949.
54. Tudor G, Gutierrez P, Aguilera-Gutierrez A, Sausville EA. Cytotoxicity and apoptosis of benzoquinones: redox cycling, cytochrome c release, and BAD protein expression. Biochem Pharmacol 2003;65:1061-1075.
55. Rascher A, Hu Z, Viswanathan N, et al. Cloning and characterization of a gene cluster for geldanamycin production in Streptomyces hygroscopicus NRRL 3602. FEMS Microbiol Lett 2003;218:223-230.
56. Faulkner DJ. Marine natural products. Nat Prod Rep 2002;19:1-48.
57. Haygood MG, Schmidt EW, Davidson SK, Faulkner DJ. Microbial symbionts of marine invertebrates: opportunities for microbial biotechnology. J Mol Microbiol Biotechnol 1999;1:33-43.
58. Hildebrand M, Waggoner LE, Lim GE, Sharp KH, Ridley DP, Haygood MG. Approaches to identify, clone and express symbiont bioactive metabolite genes. Nat Prod Rep 2004;21:122-142.
59. Pfeifer BA, Admiraal SJ, Gramajo H, Cane DE, Khosla C. Biosynthesis of complex polyketides in a metabolically engineered strain of E. coli. Science 2001;291:1790-1792.
60. Pfeifer B, Hu Z, Licari P, Khosla C. Process and metabolic strategies for improved production of Escherichia coli-derived 6-deoxyerythronolide B. Appl Environ Microbiol 2002;68:3287-3292.
61. Dayem LC, Carney JR, Santi DV, Pfeifer BA, Khosla C, Kealey JT. Metabolic engineering of a methylmalonyl-CoA mutase-epimerase pathway for complex polyketide biosynthesis in Escherichia coli. Biochemistry 2002;41:5193-5201.
62. Murli S, Kennedy J, Dayem LC, Carney JR, Kealey JT. Metabolic engineering of Escherichia coli for improved 6-deoxyerythronolide B production. J Ind Microbiol Biotechnol 2003;30:500-509.
63. Lau J, Tran C, Licari P, Galazzo JL. Development of a high cell-density fed-batch bioprocess for the heterologous production of 6-deoxyerythronolide B in Escherichia coli. J. Biotechnol 2004;110:95-103.
64. Kumar P, Li Q, Cane DE, Khosla C. Intermodular communication in modular polyketide synthases: structural and mutational analysis of linker mediated protein-protein recognition. J Amer Chem Soc 2003;125:4097-4102.
65. Gokhale RS, Tsuji SY, Cane DE, Khosla C. Dissecting and exploiting intermodular communication in polyketide synthases. Science 1999;284:482-485.
66. Wu N, Tsuji SY, Cane DE, Khosla C. Assessing the balance between protein-protein interactions and enzyme-substrate interactions in the channeling of intermediates between polyketide synthase modules. J Amer Chem Soc 2001;123:6465-6474.
67. Broadhurst RW, Nietlispach D, Wheatcroft MP, Leadlay PF, Weissman KJ. The structure of docking domains in modular polyketide synthases. Chem Biol 2003;10:723-731.
68. Hutchinson CR. Biosynthetic Studies of daunorubicin and tetracenomycin C. Chem Rev 1997;97:2525-2536.